440 Topical phosphodiesterase 4 (PDE4) inhibitor crisaborole (crisa) improves skin transcriptomic and proteomic biomarkers of mild-to-moderate AD towards normal skin

A Pavel,E Del Duca,J Cheng,P Facheris,Y Estrada,A Cha,J Werth,R Bissonette,K Nocka,C Zang,E Guttman-Yassky

doi:10.1016/j.jid.2022.05.449

440 Topical phosphodiesterase 4 (PDE4) inhibitor crisaborole (crisa) improves skin transcriptomic and proteomic biomarkers of mild-to-moderate AD towards normal skin

A Pavel, E Del Duca + Show 9 more

Open Access

https://doi.org/10.1016/j.jid.2022.05.449

Copy DOI

Journal: The Journal of investigative dermatology	Publication Date: Jul 20, 2022
License type: publisher-specific-oa

Affiliation: Icahn School of Medicine at Mount Sinai, University of Mississippi, Pfizer (United States), Innovaderm (Canada)

#Nonlesional Skin #Normal Skin + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

This study was conducted to identify changes in genomic and proteomic skin profiles of 40 patients with AD lesions treated with crisa, a nonsteroidal PDE4 inhibitor, and vehicle and compare them to those of nonlesional (NL) and normal (N) skin. 2 randomly assigned (1:1 intrapatient manner) target lesions were treated with crisa or vehicle BID for 14 days. Punch biopsies were collected from lesional and nonlesional skin from patients with AD and 20 healthy controls at baseline and days 8/15 of treatment.

Full Text